NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free SYRS Stock Alerts $5.07 -0.07 (-1.36%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.00▼$5.2050-Day Range$4.50▼$7.7552-Week Range$2.09▼$8.17Volume89,634 shsAverage Volume275,024 shsMarket Capitalization$135.52 millionP/E RatioN/ADividend YieldN/APrice Target$14.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Syros Pharmaceuticals alerts: Email Address Syros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside182.7% Upside$14.33 Price TargetShort InterestBearish9.89% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$747 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.78) to ($3.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector177th out of 907 stocksPharmaceutical Preparations Industry63rd out of 418 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.89% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Syros Pharmaceuticals has recently increased by 4.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 64.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.88. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search Interest6 people have searched for SYRS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $747.00 in company stock.Percentage Held by Insiders10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($3.78) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Syros Pharmaceuticals Stock (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesApril 18, 2024 | americanbankingnews.comSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.comApril 17, 2024 | americanbankingnews.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38April 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. April 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 9, 2024 | msn.comSyros jumps on FDA fast track tag for leukemia drugApril 9, 2024 | markets.businessinsider.comFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid LeukemiaApril 9, 2024 | businesswire.comSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionApril 2, 2024 | businesswire.comSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. March 29, 2024 | investing.comEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsMarch 29, 2024 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene TrialsMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 27, 2024 | markets.businessinsider.comSyros Pharmaceuticals earnings preview: what Wall Street is expectingMarch 27, 2024 | investorplace.comSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial DevelopmentsMarch 27, 2024 | businesswire.comSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateMarch 25, 2024 | finance.yahoo.comSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialMarch 20, 2024 | businesswire.comSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024March 16, 2024 | finance.yahoo.comSYRS Apr 2024 10.000 callMarch 11, 2024 | msn.comFibroGen appoints Deyaa Adib as Chief Medical OfficerFebruary 28, 2024 | finance.yahoo.comSYRS Jul 2024 2.500 callFebruary 27, 2024 | finance.yahoo.comInvestors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past yearFebruary 27, 2024 | finance.yahoo.comSyros to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | businesswire.comSyros to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 23, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS)See More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+182.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-164,570,000.00 Net Margins-1,656.34% Pretax Margin-1,656.34% Return on Equity-227.91% Return on Assets-75.60% Debt Debt-to-Equity Ratio2.07 Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$9.94 million Price / Sales13.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book6.42Miscellaneous Outstanding Shares26,730,000Free Float23,935,000Market Cap$135.52 million OptionableOptionable Beta1.74 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Richard A. Young Ph.D. (Age 70)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $108.37kDr. David A. Roth M.D. (Age 61)Chief Medical Officer Comp: $679.52kMr. Conley Chee (Age 54)CEO, President & Director Dr. James E. Bradner M.D. (Age 52)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Jason Haas (Age 56)Chief Financial Officer Comp: $457.22kMs. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 56)J.D., Chief Legal Officer & Head of Business Development Comp: $127.07kMs. Lisa RobertsVice President of Human ResourcesMs. Kristin Stephens (Age 51)Chief Development Officer More ExecutivesKey CompetitorsSagimet BiosciencesNASDAQ:SGMTAmylyx PharmaceuticalsNASDAQ:AMLXBiophytisNASDAQ:BPTSAnnovis BioNYSE:ANVSVistagen TherapeuticsNASDAQ:VTGNView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 144,869 shares on 4/24/2024Ownership: 0.636%David RothSold 150 sharesTotal: $747.00 ($4.98/share)Flagship Pioneering Inc.Bought 300,000 shares on 2/15/2024Ownership: 6.141%Opaleye Management Inc.Bought 359,370 shares on 2/15/2024Ownership: 1.706%Avidity Partners Management LPBought 92,396 shares on 2/14/2024Ownership: 7.943%View All Insider TransactionsView All Institutional Transactions SYRS Stock Analysis - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price target for 2024? 2 Wall Street research analysts have issued 1 year price objectives for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $13.00 to $15.00. On average, they expect the company's share price to reach $14.33 in the next year. This suggests a possible upside of 182.7% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2024? Syros Pharmaceuticals' stock was trading at $7.79 at the beginning of 2024. Since then, SYRS stock has decreased by 34.9% and is now trading at $5.07. View the best growth stocks for 2024 here. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its earnings results on Wednesday, March, 27th. The company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.04. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $2.40 million. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative trailing twelve-month return on equity of 227.91%. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals shares reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.64%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
